One of the biggest patent cliffs is set to hit the pharmaceutical industry this decade, with major players bracing for a blow ...

The session focused on the evolution of stroke care, particularly ischemic strokes, which make up 87% of all strokes. It ...

During medical emergencies, when decisions must be made quickly, knowing how blood thinners are affecting a person’s ability ...

A 70-year-old man was taken to the emergency room due to sudden difficulty in breathing. The diagnostic result is 'Closed ...

AstraZeneca's anticoagulant reversal agent Andexxa was given an accelerated approval by the FDA in 2018, but the company's plan to get that upgraded to a full approval is facing some pushback. At ...

Bristol-Myers Squibb's Eliquis (apixaban) for prevention and treatment of blood clots – down 56% to $231.00; Novartis' Entresto (valsartan/sacubitril) for heart failure – down 53% to $295.00; and ...